Prepared for
Digital Health
Hero Finding
A vast majority would partially or completely replace their current RCM benchmarking tools with a standalone solution: vendor consolidation is the dominant buying motion, not net new spend.
When asked how the proposed RCM benchmarking solution would fit alongside existing tools, only a small minority described it as a supplement. About half would partially replace current tools and roughly a third would completely replace them. Replacement intent rises with size: a strong majority of organizations in the larger NPR segment said the solution could replace what they have today, versus about a third in the smaller NPR segment. Strong investment intent and concept interest reinforce that the demand signal is for consolidation rather than another add-on.
Vast majority
Would partially or completely replace current RCM benchmarking tools
Strong majority
Top two box likelihood to invest in the proposed solution
Mid-six-figure
Acceptable annual price band from Van Westendorp analysis
Majority
Cite a 6 to 12 month evaluation to purchase timeline
Study Design
N=49 senior healthcare finance and revenue cycle decision-makers across IDNs, AMCs, and community and specialty hospitals.
The sample was built to represent the buying committee for an RCM benchmarking purchase: CFOs who control the budget alongside RCM directors and VPs who own day-to-day tool selection. All participants are current users of at least one RCM benchmarking solution, which keeps the conversation grounded in lived gaps rather than hypothetical needs.
Sample segmentation
IDN · 22
Academic Medical Center · 16
Community Hospital · 8
Specialty or Children's · 3
Interview guide · core topics
- Definition of RCM benchmarking and the metrics in scope versus out of scope
- Current tool stack: EHR add-ons, association data, internal systems, and standalone vendors
- Met and unmet needs across front-end, mid-cycle, and back-end revenue cycle
- Concept reaction to a comprehensive standalone RCM benchmarking solution
- Required capabilities: peer cohorts, prescriptive insights, workflow integration, AI
- Vendor perception and category authority across incumbents and the proposed offering
- Willingness to pay using Van Westendorp price sensitivity methodology
- Adoption strategy, evaluation to purchase timeline, and replace versus supplement intent
Recruit criteria
- Director level or above in finance, revenue cycle management, or financial planning
- Primary decision-maker or significant influencer on RCM benchmarking tool selection
- Health system or hospital meeting a meaningful annual net-patient-revenue floor
- Active user of one or more RCM benchmarking tools for at least six months
Key Findings
What the research surfaced for the commercial strategy.
Six findings defined the category opportunity, the capability bar, and the pricing window for a standalone RCM benchmarking solution.
Vast majority
Would partially or completely replace current tools
Majority
Top two box concept interest
Strong majority
Top two box likelihood to invest
~½
Very likely to switch from their current solution
Mid-six-figure
Optimal annual price band across the full sample
Majority
Cite a 6 to 12 month evaluation to purchase cycle
01
The market is fragmented and the gap is in peer cohorts and actionable insight: peer cohort limitations and the absence of prescriptive intelligence are the most significant unmet needs.
A strong majority of participants define RCM benchmarking as comparing their performance against external peers and industry standards. Yet today's tools fail at exactly that comparison. EHR-tied benchmarking and association data each lead current usage at materially similar rates, with internal systems behind, and the vast majority stitch these together to identify performance gaps. The shared complaint is that current peer cohorts do not match their organization type, payer mix, or patient population, and that the data arrives as raw metrics without guidance on what to do next.
02
Replacement intent is the dominant buying motion: a vast majority would partially or completely replace existing tools, with the strongest signal in larger systems.
Only a small minority of participants described the proposed solution as a supplement. About half would partially replace existing tools and roughly a third would completely replace them. The replacement signal is strongest in the larger NPR segment (a strong majority would replace) versus the smaller NPR segment (about a third). About half of the full sample said they are very likely to switch from their current solution. Commercial strategy needs to be built around displacing incumbents, not adding to them.
03
Add-on inertia is real even when satisfaction is mediocre: a meaningful share of add-on users continue because the tool fits an existing vendor agreement, not because it works.
About half of participants using add-on benchmarking solutions cite that they 'adequately meet our needs.' But a meaningful share cite 'fits within existing vendor agreements' as the primary reason for continued use, and that share is materially higher among CFOs than among RCM leads. EHR-tied benchmarking and association tools rate roughly equivalent on needs fit, both well below internal data systems. The add-on incumbent advantage is procurement convenience, not product quality.
04
Three capabilities are non-negotiable: integration with the EHR, prescriptive recommendations, and real-time operational intelligence.
A meaningful share of participants require seamless integration as a prerequisite for purchase, and a meaningful share express explicit concerns about integration and technical implementation complexity. A smaller share specifically seek intelligent analytics and prescriptive guidance, and a smaller share cite the evolution from raw metrics to actionable intelligence as the differentiator. A meaningful share want comprehensive front to back revenue cycle coverage. Static periodic reporting is no longer sufficient at clinical scale.
05
Optimal annual price falls in a mid-six-figure band with willingness to pay scaling with size.
Van Westendorp price sensitivity analysis across the full sample places the optimal price point in a mid-six-figure annual band, with the indifference price modestly above and the point of marginal expensiveness materially above the optimal. The larger NPR segment shows materially higher willingness to pay versus the smaller NPR segment. A meaningful share of participants currently spend within or above this band annually on RCM benchmarking, so the recommended price aligns with current spending while consolidating fragmented budgets.
06
ROI proof is both the unlock and the barrier: it appeared as the top driver and the top obstacle to switching, with 6 to 12 month evaluation cycles for the majority of participants.
When asked what would drive or hinder a switch to a new RCM benchmarking solution, ROI and financial justification appeared as both the primary driver and the most critical barrier. A smaller share of participants favor performance-based pricing models, mirroring their own value-based payer contracts, and a smaller share prioritize structures that reflect a multi-year partnership. The category authority gap also matters: a strong majority view the proposed brand's expertise as translating well to RCM benchmarking, but EHR-tied incumbents still lead materially on this dimension.
“Consolidating the data into one solution and one annual spend would be extremely beneficial, assuming this single solution could meet the needs of all the different stakeholders across the front to back revenue cycle.”— RCM Lead, Academic Medical Center, larger NPR segment
Crosstab · Replacement Intent and Pricing by NPR Segment
Replacement intent and willingness to pay both scale with net patient revenue, with the largest health systems demonstrating the strongest commercial signal.
Concept reception, replacement intent, and Van Westendorp pricing thresholds, segmented by net patient revenue, indexed within row to peak segment = 100. The larger NPR segment is the higher-receptivity early target across every commercial signal in the dataset.
| Larger NPR segment (n=25) | Smaller NPR segment (n=24) | |
|---|---|---|
| Solution would replace current tools | 100 | 52 |
| Strong concept interest (top two box) | 100 | 78 |
| Likely to invest (top two box) | 100 | 79 |
| Very likely to switch from current tool | 100 | 73 |
| Optimal Price Point (OPP) | 100 | 81 |
| Indifference Price Point (IPP) | 100 | 62 |
| Point of Marginal Expensiveness (PME) | 100 | 60 |
N=49 health system finance and RCM decision-makersIndexed · blinded valuesReplacement intent and WTP both materially higher in the larger NPR segment
Voice of Customer
How health system finance and RCM leaders describe the gap and the opportunity.
Verbatims from the research, selected to represent the range of views on fragmentation, prescriptive intelligence, ROI proof, and pricing structure.
Consolidation Intent · Vendor Reduction
“As an organization, we already have several revenue cycle management providers. So we are not looking to add a new vendor. What we would be looking for is to consolidate and have fewer vendors.”
— RCM Lead, Academic Medical Center, larger NPR segment
Prescriptive Gap · Raw Metrics Today
“Right now, we only get the metrics and the data. But we do not get actionable insights based on the analysis of the data.”
— RCM Lead, Academic Medical Center, larger NPR segment
Cohort Relevance · Population Fit
“The current benchmarking tools that we utilize are very general. They do not meet the unique populations that we serve. Our organization serves rural communities, and there are no specific tools that meet these types of patient populations, demographics, and payers.”
— RCM Lead, Integrated Delivery Network, smaller NPR segment
Real-Time Visibility · System Sprawl
“Currently, we use disparate systems that exist in the front, mid, and back-end revenue cycle that don't speak to each other and don't share things like dashboards and insights in real time.”
— RCM Lead, Academic Medical Center, larger NPR segment
Pricing Structure · Performance Alignment
“Performance-based model aligns incentives. If you believe in your solution, that you're going to be able to deliver value-added revenues, then that would be one you should be willing to go forth on, every day of the week.”
— RCM Lead, Community Hospital, smaller NPR segment
ROI Threshold · Switching Justification
“Since RCM benchmarking has a direct relationship with our bottom line or revenue, it provides a good ROI. Therefore, it makes sense for our organization to invest in such a tool.”
— RCM Lead, Integrated Delivery Network, smaller NPR segment
Counter-intuitive
Adequate-but-not-excellent is the incumbent's moat, and procurement is a bigger barrier than capability.
The prevailing assumption inside the strategy team was that current tools would underperform on satisfaction and that a clearly better product would win on its merits. The data shows something subtler. About half of add-on users describe their tools as adequately meeting needs, and EHR-tied benchmarking rates only modestly above the midpoint. The lock-in is not satisfaction, it is the existing vendor agreement: a meaningful share of add-on users continue because the tool fits an existing contract, rising materially among CFOs. A standalone challenger has to clear two thresholds, not one. The product needs to be visibly better on cohorts, prescriptive guidance, and integration, and the commercial motion needs to make procurement easier than renewing the bundled add-on. ROI proof is what gets a buyer to break that procurement gravity, which is why it appears as both the top driver and the top barrier in the same dataset.
Strategic Implications
Three commercial strategy moves from the research.
What the team carried into commercial planning, grounded in the replacement intent data, the capability requirements, and the Van Westendorp pricing window.
01
Position as a vendor consolidation play, not an add-on, and target the larger NPR segment for category launch.
A vast majority of the sample would partially or completely replace existing tools, and the larger NPR segment shows higher replacement intent, higher invest intent, higher switch likelihood, and materially higher willingness to pay. Sales motion, packaging, and reference customer strategy should all be built for the consolidation buyer rather than the supplemental purchase.
02
Build the product around three non-negotiables: relevant peer cohorts, prescriptive guidance, and EHR-grade integration.
Peer cohort limitations and the absence of prescriptive intelligence are the top unmet needs. A meaningful share require seamless integration as a prerequisite. The first release has to deliver organization-type and payer-mix-relevant cohorts, recommendations attached to every benchmark, and a productized integration path with the dominant EHR. Anything less and the buyer reverts to the existing add-on.
03
Anchor pricing in the mid-six-figure annual band with a tiered model and an optional performance-based structure for the largest accounts.
Van Westendorp places the OPP in a mid-six-figure annual band, with the IPP modestly above and a material premium in the larger NPR segment. A strong majority prefer flat annual subscription, a meaningful share accept multi-year with discounts, and a smaller share favor performance-based structures that mirror their payer contracts. The recommended package: a flat annual base for the standard tier, multi-year options for committed buyers, and a performance-aligned structure available for enterprise pursuits to break ROI deadlocks.
Success criteria · 12 months
- Two reference customers in the larger NPR segment with documented replacement of incumbent tools within the first commercial year
- Productized integration with the dominant EHR validated and live before category launch
- Median time from first meeting to signed contract held within the 6 to 12 month buyer window for the majority of opportunities
- ROI case study with quantified bottom-line impact published within nine months of first deployment
Risk register
| Category authority gap versus EHR incumbent | HIGH |
| Procurement gravity of bundled add-on agreements | HIGH |
| Integration and technical implementation risk | HIGH |
| ROI proof timeline versus 6 to 12 month buying cycle | MED |
| Smaller NPR segment willingness to pay | MED |